Background Epicardial adipose tissue (EAT) is a risk factor for cardiovascular diseases.
Glucagon-like peptide 1 analogs (GLP-1A) may have beneficial cardiovascular effects and …

Epicardial adipose tissue (EAT) is an easily measurable visceral fat of the heart with unique
anatomy, functionality, and transcriptome. EAT can serve as a therapeutic target for …

Aims Human epicardial adipose tissue (EAT) plays a crucial role in the development and
progression of coronary artery disease, atrial fibrillation, and heart failure. Microscopically …

Epicardial adipose tissue is a novel cardiovascular risk factor. It plays a role in the
progression of coronary artery disease, heart failure and atrial fibrillation. Given its rapid …

Abstract Background and Aims Epicardial adipose tissue (EAT), the visceral fat depot of the
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …

Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area
appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and …

Increased expression of receptor for advanced glycation end products (RAGE) in adipose
tissue has been associated with inflammation, adipocyte hypertrophy, and impaired insulin …

Objective To explore the transcriptome of epicardial adipose tissue (EAT) as compared to
subcutaneous adipose tissue (SAT) and its modifications in a small number of patients with …

Abstract Glucagon-like peptide 1 (GLP-1) has insulin-like effects on myocardial glucose
uptake which may contribute to its beneficial effects in the setting of myocardial ischemia …

Patients with obesity have been historically associated with higher risk to develop
cardiovascular diseases (CVD). However, regional, visceral, organ specific adiposity seems …